OBJECTIVE: To investigate the relationship between C-reactive protein (CRP) and various characteristics of the metabolic syndrome. DESIGN: Population-based cross-sectional study. SUBJECTS: A total of 1929 subjects undergoing a medical examination in a preventive medicine clinic (age, 50710 y; 63% males). RESULTS: The proportion of subjects with CRP levels above the cut point generally used to indicate an obvious source of infection or inflammation (410 mg/l) was 3, 7, and 15% in subjects who were normal weight, overweight, and obese, respectively. Subjects with obesity had markedly higher CRP level compared to patients without obesity regardless of whether they had the metabolic syndrome. However, there was no significant difference in CRP levels between nonobese subjects without the metabolic syndrome and subjects in whom the diagnosis of the metabolic syndrome was based on criteria other than obesity (adjusted geometric mean CRP 1.75 vs 2.08 mg/l, P ¼ 0.79). Similarly, CRP levels did not differ among obese subjects with and without the metabolic syndrome (adjusted geometric mean CRP 3.22 vs 3.49 mg/l, P ¼ 0.99). There was a linear increase in CRP levels with an increase in the number of metabolic disorders (P trend o0.0001), which was substantially diminished after controlling for body mass index (BMI) (P trend ¼ 0.1). Stepwise multivariate linear regression analysis identified BMI, triglyceride levels, HDL cholesterol levels (inversely), and fasting glucose as independently related to CRP levels. However, BMI accounted for 15% of the variability in CRP levels, whereas triglycerides, HDL cholesterol and fasting glucose levels accounted for only B1% of the variability in CRP levels. CONCLUSION: Obesity is the major factor associated with elevated CRP in individuals with the metabolic syndrome. CRP levels in the range suggesting a source of infection or inflammation (410 mg/l) are more common among obese subjects than in nonobese subjects.
Introduction
Arterial inflammation has emerged as central to the initiation and progression of atherosclerosis. 1, 2 Of the markers of inflammation, C-reactive protein (CRP) has been shown in multiple prospective studies to predict incident myocardial infarction, stroke, peripheral vascular disease, and sudden cardiac death. 3, 4 The proportion of overweight adults in the US has been steadily increasing in the past several decades. Presently, most US adults are overweight (450%), and approximately one in five are obese (body mass index (BMI)Z30 kg/m 2 ). 5 Each year, an estimated 300 000 US adults die of causes related to obesity. 6 In particular, obesity is associated with the metabolic syndrome, development of type II diabetes and coronary heart disease. 7 Obesity independently predicts coronary atherosclerosis, 8 coronary events, and coronary mortality. 9, 10 Recent studies have shown that elevated CRP is strongly associated with various characteristics of the metabolic syndrome. [11] [12] [13] [14] [15] A growing body of evidence implicates adipose tissue as a major regulator of inflammation, coagulation, and fibrinolysis. Adipose tissue produces proinflammatory cytokines such as tumor necrosis factor-a and interleukin-6, 14, 16 and is considered an important source of basal production of interleukin-6, the chief stimulator of the production of CRP in the liver. 17 In the present cross-sectional study of middle-aged subjects, we examine the relation between plasma CRP concentrations, obesity, and other characteristics of the metabolic syndrome.
Subjects and methods

Subjects
We studied 1929 middle-aged subjects who reported to the Rambam Center for Preventive Medicine for investigation of cardiovascular risk factors. Subjects with evidence for an overt inflammatory disease were excluded. The participating subjects came to the Rambam Medical Center for a medical examination and health counseling. Some were sent by their employers for these services, some were referred by their personal physician, and others were self-referred.
A medical history was taken by a physician in all subjects. The investigational review committee on human research approved the study. Subjects enrolled in the study signed a statement agreeing to use their medical information for research purposes.
Definitions
BMI was used as an estimate of overall adiposity. Cigarette smoking was dichotomized into 'never' or 'ever' (including past and current) by use of standard questionnaire. Leisure time physical activity was also dichotomized to never, rarely, or regular physical activity.
Categories of overweight and obesity were constructed based on the graded classification that applies to both men and woman proposed by a World Health Organization expert committee: 18 20 Subjects with Z3 of the above criteria were diagnosed as having the metabolic syndrome. If the participants were using antihypertensive or antidiabetic medications (oral agents or insulin), they were considered as participants with high blood pressure or diabetes, respectively.
Laboratory measurements
Venous blood samples were collected from each subject after a 12-h fast and used for assay of glucose, total and HDL cholesterol, triglycerides, and uric acid. Triglycerides were determined by using a reagent kit from Boehringer Mannheim after enzymatic hydrolysis of the triglycerides and subsequent determination of liberated glycerol by colorimetry. Total cholesterol was measured with an automated enzymatic method using a high-performance reagent kit from Boehringer Mannheim. HDL cholesterol was measured by the phosphotungstate method. Plasma glucose was enzymatically determined with the glucose oxidase method using AutoAnalyzer (Hitachi Inc., Tokyo, Japan). Complete blood cell counts were performed with standard techniques. CRP was measured with latex-enhanced immunonephelometry on a Behring BN II Nephelometer (Dade Behring, Newark, DE, USA). In this assay, polystyrene beads coated with mouse monoclonal antibodies bind CRP present in the serum sample, and form aggregates. The intensity of the scattered light is proportional to the size of the aggregates and thus reflects concentration of CRP present in the sample. The intra-assay and interassay CVs for CRP were 3.3 and 3.2%, respectively. The lower detection limit of the assay was 0.15 mg/l. In nine subjects, CRP levels were lower than this value. A value of 0.15 mg/l was assigned to these subjects.
Statistical methods
Differences between CRP levels in subjects with and without each of the characteristics of the metabolic syndrome were compared using the Mann-Whitney Rank Sum test. The distribution of CRP levels was highly skewed. Therefore, CRP values were transformed to their natural logarithm (ln CRP) for all other analyses. The adjusted mean values of ln CRP in relation to the number of metabolic disorders were calculated by analysis of covariance (ANCOVA), with results expressed as geometric means. Using a general linear model, we tested the significance of trends for increasing CRP levels across the number of metabolic disorders.
The strength of the association between CRP and clinical and biochemical variables was assessed by linear regression of ln CRP on each variable separately. Subsequently, stepwise linear regression models were fit for ln CRP as a dependent variable, including all variables of interest as independent variables to demonstrate the relative contribution of each of these variables to the outcome variable. Only variables that had a Pr0.05 were considered in the final fitted model. Differences were considered significant at the Po0.05 level.
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All statistical analyses were performed using the SPSS statistical software (version 10.1).
Results
The study population included 1929 subjects (mean age 50710 y (range 32-78), 63% males). More than 95% of subjects were Caucasian. The median plasma concentrations of CRP were lowest among participants with normal BMI (1.2, interquartile range 0.7-2.6 mg/l), higher among overweight individuals (1.9, interquartile range 1.0-4.2 mg/l), and highest among individuals with obesity (4.0, interquartile range 2.0-7.3 mg/l). CRP levels increased continuously with increasing severity of obesity (Figure 1a) .
The proportion of subjects with CRP levels above the cut point, generally used to indicate an obvious source of infection or inflammation (410 mg/l), 21, 22 increased with higher levels of obesity, with a substantial proportion of obese subjects having CRP above this cut point (Figure 1b) . The WBC count was significantly higher in subjects with CRP 410 mg/l compared with subjects with CRP r10 mg/l (6.771.7 vs 8.172.1 ( Â 10 9 l À1 ); Po0.0001). Nonobese subjects without the metabolic syndrome had the lowest CRP levels. Subjects with obesity had markedly higher CRP level compared to patients without obesity regardless of whether they had the metabolic syndrome ( Figure 2 ). However, there was no significant difference in CRP levels between nonobese subjects without the metabolic syndrome and subjects in whom the diagnosis of the metabolic syndrome was based on criteria other than obesity (P ¼ 0.79). Similarly, CRP levels did not differ among obese subjects with and without the metabolic syndrome (P ¼ 0.99).
CRP levels were significantly higher in subjects who had each characteristic of the metabolic syndrome, compared to those who did not ( Table 1 ). The percentage of subjects presenting with 0, 1, 2, 3, 4, or 5 components of the metabolic syndrome was 44, 29, 16, 8, 2, and 1%, respectively. There was a strong linear increase in ln CRP with increasing number of metabolic disorders (Figure 3a) . BMI increased continuously with increasing number of components of the metabolic disorders; the geometric mean CRP for those with 0, 1, 2, 3, 4, and 5 components of the metabolic syndrome were 1.48, 2.31, 2.66, 3.19, 3.42, and 3.86 mg/l, respectively. However, controlling for BMI substantially diminished the trend across characteristics of the metabolic syndrome (Figure 3b ).
There was a statistically significant unadjusted relation correlation between ln CRP and all components of the 
Figure 2
Adjusted geometric means CRP and 95% confidence intervals for subjects without both the metabolic syndrome and obesity (MSÀ, ObÀ), subjects with the metabolic syndrome based on components other than obesity (MS þ , ObÀ), subjects with obesity but without the metabolic syndrome (MSÀ, Obþ ) and subjects with the diagnosis of the metabolic syndrome when one of the components is obesity (MS þ , Ob þ ). CRP levels were adjusted for age, sex, WBC count, serum albumin, physical activity, smoking status, and HRT using ANCOVA. Table 2 ). The strongest correlation (r ¼ 0.39) was observed between CRP and BMI. After adjustment for potential confounders in a stepwise multivariate linear regression analysis, all components of the metabolic syndrome remained significantly and independently related to CRP levels, except for hypertension (Table 3) . However, although triglycerides, HDL cholesterol, and glucose levels were independently associated with ln CRP, they accounted for B1% of the variability in ln CRP, whereas BMI accounted for 15% of the variability in CRP levels. Stepwise multivariate linear regression analysis also identified hormone replacement therapy, WBC count, and serum albumin as independently associated with ln CRP levels ( Table 3) .
Discussion
In this sample of middle-aged subjects, components of the metabolic syndrome were strongly related to plasma concentrations of CRP, independent of other factors known to influence CRP levels, such as smoking, HRT, and physical activity. Levels of CRP increased continuously with increasing number of metabolic disorders. However, BMI was the dominant contributor to CRP levels among subjects with the metabolic syndrome. In addition, CRP levels consistent with active inflammation were common in obese subjects. Previous studies have shown that components of the metabolic syndrome cluster with elevation of acute phase reactants. [11] [12] [13] [14] [15] 23 Our results confirm recent observations that in middle-aged subjects, CRP levels are strongly associated with various characteristics of the metabolic syndrome. However, the association between measures of metabolic risk and CRP was mainly related to overall obesity. First, subjects with the metabolic syndrome had higher CRP levels than subjects without the metabolic syndrome only if they were obese. Subjects with obesity had markedly higher CRP level compared to patients without obesity regardless of whether they had the metabolic syndrome, and nonobese patients had comparable CRP levels regardless of whether they had the metabolic syndrome. Second, the effect of increasing number of metabolic disorders on CRP levels Obesity and CRP D Aronson et al described in previous studies 12 was markedly attenuated after accounting for BMI. Third, multivariate regression analysis indicated that among the components of the metabolic syndrome, BMI contributes most of the variance in CRP levels. Recent guideline suggest that if CRP level of 410 mg/l is identified, there should be a search initiated for an obvious source of infection or inflammation, and that the result of the test should then be discarded. 22 Although only 7.6% of subjects had CRP values greater than the generally accepted cutoff for inflammation, our results suggest that these values are most frequently associated with overweight and especially with obesity. Therefore, CRP results should always be interpreted in the context of the subject's BMI, as very high levels may be expected in severely obese subjects. One of the explanations for increased CRP concentrations in subjects with the metabolic syndrome relates to the potential effect of body fat. Both tumor necrosis factor-a and interleukin-6 are expressed in, and released by adipose tissue. 14, 16 There is a close relationship between circulating CRP and cytokine concentrations 14 and between CRP concentrations and anthropometric measures of obesity. 14, 15 Since the synthesis of CRP by the liver is predominantly regulated by inteleukin-6, 17 it is believed that interleukin-6
originating from adipose tissue contributes to the raised CRP concentrations in obese insulin-resistance subjects. Tumor necrosis factor-a does not induce CRP directly, but can potentiate the induction of CRP by interleukin-6.
24
This hypothesis is consistent with the strong relationship between BMI and CRP levels. [11] [12] [13] [14] [15] 25 However, the existence of an association between CRP and insulin resistance independent of body mass is controversial. As obesity induces insulin resistance and inflammatory cytokines are secreted by adipose tissue, it is difficult to exclude the possibility that the relationship between markers of systemic inflammation and measures of insulin resistance reflects residual confounding of the stronger relationship between obesity and insulin resistance. For example, inflammatory cytokines originating from adipose tissue induce insulin resistance by direct action on the insulin-signaling cascade 26, 27 and stimulate CRP production by the liver. 17, 24 Some studies describe an independent inverse association between measures of insulin resistance and CRP. 12, 28 By contrast, other studies failed to identify a relationship between serum markers of inflammation and measures of insulin resistance after controlling for the effect of obesity. [29] [30] [31] Inflammation is a modifiable risk factor amenable to improvement by drugs 4 and lifestyle modifications. Weight loss has been associated with a concomitant decrease in CRP and cytokine levels. 32, 33 In the context of the present study, it is important to emphasize that weight loss is probably the most useful intervention to ameliorate the proinflammatory state associated with the metabolic syndrome.
Study limitations
The prevalence of the metabolic syndrome has varied between different studies, mostly because of the lack of accepted criteria for the definition of the syndrome. Recently, both the World Health Organization 20 and the ATP-III 19 proposed unifying definitions for the syndrome.
We defined components of the metabolic syndrome based on a combination of the ATP-III and WHO criteria. This definition differs from the full ATP-III criteria in that obesity is defined based on BMI rather than waist circumference. 19, 20 However, Ridker et al 34 
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Conclusion
Obesity is the major factor associated with elevated CRP in individuals with the metabolic syndrome. CRP levels in the range suggesting a source of infection or inflammation (410 mg/l) are more common among obese subjects than in nonobese subjects.
